Eisai Adds To Alzheimer's Arsenal With Anti-Tau Drug

 
• By Kevin Grogan

It is a field littered with failures but Eisai remains hopeful that its pipeline of candidates for Alzheimer's disease, which has just been added to, gives the firm a number of shots at getting a disease-modifying agent to market.

alone at the summit climber & successful climbers
Surveying the Alzheimer's landscape • Source: Shutterstock

More from Neurological

More from Therapy Areas